2024 ASCO Annual Meeting
Shorter Durations of Venetoclax Yield Similar Response Rates Compared to Standard Course in AML
When combined with azacitidine, a 7-day course of venetoclax demonstrated similar remission rates and was more tolerable compared to the standard 28-day course for older or chemotherapy-ineligible pat...
Relapsed or Refractory B-Cell ALL: Novel CAR T-Cell Therapy Yields Strong Remission Rates
The novel anti-CD19 autologous chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel achieved durable remissions in 40% of patients with relapsed or refractory B-cell acute lymphoblas...
American Cancer Society and ASCO Announce Expanded Patient-Centered Online Collaboration
The American Cancer Society (ACS) and ASCO today announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online. The partnership between ASCO, the ...
Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07
Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patien...
Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent
Tomasz Jankowski, MD, PhD, of Poland’s Medical University in Lublin, discusses a phase II study of THIO, a telomere-targeting agent followed by cemiplimab-rwlc for a difficult-to-treat population of p...
Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib
Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lena...
Toni K. Choueiri, MD, on RCC: Biomarker Analysis From the CLEAR Trial
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab...
Muhit Özcan, MD, on CLL/SLL: Report on a Still-Recruiting International Study of Nemtabrutinib, Venetoclax, and Rituximab
Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses the ongoing phase III BELLWAVE-010 study of nemtabrutinib plus venetoclax vs venetoclax plus rituximab in previously treate...
Lorlatinib vs Crizotinib for Advanced ALK-Positive NSCLC: Extended CROWN Follow-up
The CROWN study (ClinicalTrials.gov identifier NCT03052608) of lorlatinib, a brain-penetrant, third-generation ALK tyrosine kinase inhibitor, vs crizotinib, an inhibitor of receptor tyrosine kinases (...
Asciminib Shows Superior Efficacy vs Standard-of-Care Front-Line TKIs in CML
Over the past 2 decades, the development of tyrosine kinase inhibitors (TKIs) targeting the ATP-binding site of the constitutively activated tyrosine kinase in the fusion BCR::ABL1 protein has resulte...
Can a Novel Combination Therapy Improve Metastatic Colorectal Cancer Outcomes?
A novel combination comprising experimental immunotherapy drugs plus chemotherapy may improve survival outcomes in previously treated patients with metastatic colorectal cancer compared to the targete...
Differences in Prostate Cancer Genomics Among U.S. Veterans
Researchers have uncovered differences in the genomic makeup of metastatic prostate cancer cells among U.S. veterans that may be associated with race and ethnicity. These findings will be presented by...
Cyclophosphamide May Enable More Patients With High-Risk Hematologic Malignancies to Receive Stem Cell Transplants
A novel treatment strategy using cyclophosphamide-based graft-vs-host disease prophylaxis may enable more patients with high-risk hematologic malignancies to receive stem cell transplantation from mis...
AI-Based Virtual Patient Navigator Boosts Colonoscopy Adherence
A novel artificial intelligence (AI)-based virtual patient navigator, MyEleanor, improved colonoscopy uptake among U.S. patients who were previously nonadherent to prior colonoscopy appointments. Thes...
Influence of Menopausal Hormone Therapy on Gynecologic Cancer Incidence and Mortality
In 2002, the federally funded Women’s Health Initiative—a randomized, placebo-controlled clinical trial investigating the effects of menopausal hormone therapy in healthy menopausal women—was abruptly...
HPV Vaccine Shows Prevention Efficacy for Several Types of HPV-Related Cancers in Both Males and Females
According to the Centers for Disease Control and Prevention, since the human papillomavirus (HPV) vaccine was introduced in the United States in 2006, HPV infections that cause most HPV-related cancer...
Most Breast Cancer Survivors Able to Achieve Pregnancy After Diagnosis, Study Finds
Research examining fertility preservation and pregnancy attempts among young women following a breast cancer diagnosis has been hampered by short-term follow-up and a lack of prospective assessment of...
